The Endocannabinoid System: A Potential Therapeutic Target for Coagulopathies

Overview

Journal Metabolites

Publisher MDPI

Date 2022 Jun 23

PMID 35736474

Authors

Wujood Khayat

Christian Lehmann

Affiliations

Soon will be listed here.

Abstract

Abnormal blood coagulation or coagulopathy is a common manifestation of many pathological conditions. It occurs when there is an imbalance between the activities of the coagulation system and the fibrinolytic system, leading to excessive or impaired intravascular blood clot formation, which can disturb blood flow causing ischemia or hemorrhage in the affected tissues. A growing body of evidence has demonstrated blood coagulation abnormalities in association with cannabinoid use, suggesting the involvement of the endogenous cannabinoid system (ECS) in modulating blood coagulation. However, the evidence in the literature has been controversial on whether cannabinoids promote or inhibit blood coagulation. The ECS has been extensively studied in recent years for its potential as a therapeutic target for many diseases. This review provides a brief introduction to the ECS and discusses the reported anticoagulatory and procoagulatory effects of various cannabinoids, highlighting some possible mechanisms that might underlie the observed effects. Understanding the coagulatory effects of cannabinoids and the interaction between the coagulation system and the ECS is vital for developing novel therapeutics for coagulopathies.

Citing Articles

Potential perioperative cardiovascular outcomes in cannabis/cannabinoid users. A call for caution.

Echeverria-Villalobos M, Guevara Y, Mitchell J, Ryskamp D, Conner J, Bush M Front Cardiovasc Med. 2024; 11:1343549.

PMID: 38978789 PMC: 11228818. DOI: 10.3389/fcvm.2024.1343549.

Association of Cannabis Use Disorder With Hospitalizations for Pulmonary Embolism and Subsequent in-Hospital Mortality in Young Adults: A Contemporary Nationwide Analysis.

Desai R, Ghadge N, Kanagala S, Katukuri N, James A, Kadiyala A J Am Heart Assoc. 2024; 13(13):e032787.

PMID: 38934855 PMC: 11255712. DOI: 10.1161/JAHA.123.032787.

Drug-Cannabinoid Interactions in Selected Therapeutics for Symptoms Associated with Epilepsy, Autism Spectrum Disorder, Cancer, Multiple Sclerosis, and Pain.

Campos M, China M, Claudio M, Capinha M, Torres R, Oliveira S Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794183 PMC: 11124308. DOI: 10.3390/ph17050613.

Supercritical Carbon Dioxide Technology for Recovering Valuable Phytochemicals from L. and Valorization of Its Biomass for Food Applications.

de Aguiar A, Vardanega R, Vigano J, Silva E Molecules. 2023; 28(9).

PMID: 37175258 PMC: 10180460. DOI: 10.3390/molecules28093849.

Exploring the Potential of Cannabinoid Nanodelivery Systems for CNS Disorders.

Kolesarova M, Simko P, Urbanska N, Kiskova T Pharmaceutics. 2023; 15(1).

PMID: 36678832 PMC: 9863859. DOI: 10.3390/pharmaceutics15010204.

References

Lowe H, Toyang N, Steele B, Bryant J, Ngwa W . The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases. Int J Mol Sci. 2021; 22(17). PMC: 8430969. DOI: 10.3390/ijms22179472. View

Coetzee C, Levendal R, van de Venter M, Frost C . Anticoagulant effects of a Cannabis extract in an obese rat model. Phytomedicine. 2006; 14(5):333-7. DOI: 10.1016/j.phymed.2006.02.004. View

Mir A, Obafemi A, Young A, Kane C . Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics. 2011; 128(6):e1622-7. DOI: 10.1542/peds.2010-3823. View

Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N . Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem. 2003; 279(7):5298-305. DOI: 10.1074/jbc.M306642200. View

Mallat A, Lotersztajn S . Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver. Am J Physiol Gastrointest Liver Physiol. 2007; 294(1):G9-G12. DOI: 10.1152/ajpgi.00467.2007. View

Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R . The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev. 2005; 27(1):73-100. DOI: 10.1210/er.2005-0009. View

Devgun J, Rasin A, Kim T, Mycyk M, Bryant S, Wahl M . An outbreak of severe coagulopathy from synthetic cannabinoids tainted with Long-Acting anticoagulant rodenticides. Clin Toxicol (Phila). 2019; 58(8):821-828. DOI: 10.1080/15563650.2019.1690149. View

Jiang R, Yamaori S, Takeda S, Yamamoto I, Watanabe K . Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci. 2011; 89(5-6):165-70. DOI: 10.1016/j.lfs.2011.05.018. View

Mazzola C, Micale V, Drago F . Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. Eur J Pharmacol. 2003; 477(3):219-25. DOI: 10.1016/j.ejphar.2003.08.026. View

10.

Battista N, Di Tommaso M, Bari M, Maccarrone M . The endocannabinoid system: an overview. Front Behav Neurosci. 2012; 6:9. PMC: 3303140. DOI: 10.3389/fnbeh.2012.00009. View

11.

Brantl S, Khandoga A, Siess W . Mechanism of platelet activation induced by endocannabinoids in blood and plasma. Platelets. 2013; 25(3):151-61. DOI: 10.3109/09537104.2013.803530. View

12.

Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G . Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol. 2002; 135(1):181-7. PMC: 1573125. DOI: 10.1038/sj.bjp.0704466. View

13.

Sainz-Cort A, Jimenez-Garrido D, Munoz-Marron E, Viejo-Sobera R, Heeroma J, Bouso J . Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study. J Clin Psychopharmacol. 2021; 41(5):561-570. DOI: 10.1097/JCP.0000000000001457. View

14.

Brown G, Bellnier T, Janda M, Miskowitz K . Δ-9-tetrahydrocannabinol dose increase leads to warfarin drug interaction and elevated INR. J Am Pharm Assoc (2003). 2020; 61(1):e57-e60. DOI: 10.1016/j.japh.2020.07.028. View

15.

Mang C, Erbelding D, Kilbinger H . Differential effects of anandamide on acetylcholine release in the guinea-pig ileum mediated via vanilloid and non-CB1 cannabinoid receptors. Br J Pharmacol. 2001; 134(1):161-7. PMC: 1572920. DOI: 10.1038/sj.bjp.0704220. View

16.

Maccarrone M, Bari M, Menichelli A, Del Principe D, Agro A . Anandamide activates human platelets through a pathway independent of the arachidonate cascade. FEBS Lett. 1999; 447(2-3):277-82. DOI: 10.1016/s0014-5793(99)00308-7. View

17.

Habayeb O, Taylor A, Bell S, Taylor D, Konje J . Expression of the endocannabinoid system in human first trimester placenta and its role in trophoblast proliferation. Endocrinology. 2008; 149(10):5052-60. DOI: 10.1210/en.2007-1799. View

18.

Iannotti F, Pagano E, Guardiola O, Adinolfi S, Saccone V, Consalvi S . Genetic and pharmacological regulation of the endocannabinoid CB1 receptor in Duchenne muscular dystrophy. Nat Commun. 2018; 9(1):3950. PMC: 6160489. DOI: 10.1038/s41467-018-06267-1. View

19.

Alqahtani A, Ammari Z, Ramahi A, Said Ahmed T, Klada E . Cannabis Smoking-induced Diffuse Alveolar Hemorrhage. Cureus. 2019; 11(7):e5089. PMC: 6726419. DOI: 10.7759/cureus.5089. View

20.

Grabiec U, Dehghani F . -Arachidonoyl Dopamine: A Novel Endocannabinoid and Endovanilloid with Widespread Physiological and Pharmacological Activities. Cannabis Cannabinoid Res. 2017; 2(1):183-196. PMC: 5627668. DOI: 10.1089/can.2017.0015. View